甲基2-氯-4-(甲氧基甲基)-1,3-噻唑-5-羧酸酯 | 907543-81-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 甲基2-氯-4-(甲氧基甲基)-1,3-噻唑-5-羧酸酯
• 英文名称: methyl 2-chloro-4-(methoxymethyl)thiazole-5-carboxylate
• 英文别名: methyl 2-chloro-4-(methoxymethyl)-1,3-thiazole-5-carboxylate
• CAS: 907543-81-1
• 化学式: C₇H₈ClNO₃S
• 分子量: 221.664
• InChiKey: KKCQYBRDFAUVIT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  76.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  甲基2-氯-4-(甲氧基甲基)-1,3-噻唑-5-羧酸酯 、 3,4-dichloro-N-(3S,4R)-[3-methoxypiperidin-4-yl]-5-methyl-1H-pyrrole-2-carboxamide hydrochloride Salt 在 N,N-二异丙基乙胺 作用下， 以 N-甲基吡咯烷酮 为溶剂， 以70%的产率得到methyl 2-[(3S,4R)-4-[(3,4-dichloro-5-methyl-1H-pyrrole-2-carbonyl)amino]-3-methoxy-1-piperidyl]-4-(methoxymethyl)thiazole-5-carboxylate
  参考文献：
  名称：

  Optimization of Pyrrolamide Topoisomerase II Inhibitors Toward Identification of an Antibacterial Clinical Candidate (AZD5099)

  摘要：

  AZD5099 (compound 63) is an antibacterial agent that entered phase 1 clinical trials targeting infections caused by Gram-positive and fastidious Gram-negative bacteria. It was derived from previously reported pyrrolamide antibacterials and a fragment-based approach targeting the ATP binding site of bacterial type II topoisomerases. The program described herein varied a 3-piperidine substituent and incorporated 4-thiazole substituents that form a seven-membered ring intramolecular hydrogen bond with a 5-position carboxylic acid. Improved antibacterial activity and lower in vivo clearances were achieved. The lower clearances were attributed, in part, to reduced recognition by the multidrug resistant transporter Mrp2. Compound 63 showed notable efficacy in a mouse neutropenic Staphylococcus aureus infection model. Resistance frequency versus the drug was low, and reports of clinical resistance due to alteration of the target are few. Hence, 63 could offer a novel treatment for serious issues of resistance to currently used antibacterials.

  DOI：

  10.1021/jm500462x
• 作为产物：
  描述：

  甲基2-氨基-4-(甲氧基甲基)-1,3-噻唑-5-羧酸酯 在 亚硝酸特丁酯 、 copper(l) chloride 作用下， 以 乙腈 为溶剂， 反应 3.0h， 以78 mg的产率得到甲基2-氯-4-(甲氧基甲基)-1,3-噻唑-5-羧酸酯
  参考文献：
  名称：

  [EN] DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES
  [FR] DÉRIVÉS DE DIHYDROPYRIMIDINE ET LEURS UTILISATIONS DANS LE TRAITEMENT D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B OU DE MALADIES INDUITES PAR LE VIRUS DE L'HÉPATITE B

  摘要：

  该申请描述了二氢嘧啶衍生物，其在治疗或预防HBV感染或HBV引起的疾病中是有用的，尤其是HBV慢性感染或由HBV慢性感染引起的疾病，以及它们的药物或医疗应用。

  公开号：

  WO2020001448A1

文献信息

• Antibacterial Pyrrolopyridines, Pyrrolopyrimidines and Pyrroloazepines-154
  申请人：Basarab Gregory

  公开号：US20080312211A1

  公开（公告）日：2008-12-18

  Compounds of formula (I) and their pharmaceutically acceptable salts are described: formula (I). Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

  本文描述了公式（I）的化合物及其药用可接受盐：公式（I）。还描述了它们的制备过程，包含它们的药物组合物，它们作为药物的用途以及它们在治疗细菌感染中的用途。
• ANTIBACTERIAL PIPERDINE DERIVATIVES
  申请人：Basarab Gregory

  公开号：US20100179150A1

  公开（公告）日：2010-07-15

  Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

  描述了化学式（I）的化合物及其药学上可接受的盐。描述了制备它们的过程，含有它们的药物组合物，它们作为药物的用途以及它们在治疗细菌感染中的用途。
• CHEMICAL COMPOUNDS
  申请人：AstraZeneca, Intellectual Property

  公开号：US20130150366A1

  公开（公告）日：2013-06-13

  Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use in the treatment of bacterial infections are also described.

  本文描述了化学式(I)的化合物及其药学上可接受的盐。还描述了制备它们的过程、含有它们的制药组合物，以及它们在治疗细菌感染方面的用途。
• Antibacterial piperdine derivatives
  申请人：Basarab Gregory

  公开号：US08399489B2

  公开（公告）日：2013-03-19

  Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

  本文描述了公式(I)的化合物及其药学上可接受的盐。同时还描述了它们的制备过程、包含它们的药物组合物、它们作为药物的用途以及它们在治疗细菌感染方面的应用。
• Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
  申请人：Janssen Sciences Ireland Unlimited Company

  公开号：US11053235B2

  公开（公告）日：2021-07-06

  The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.

  该申请描述了可用于治疗或预防 HBV 感染或 HBV 引起的疾病，特别是 HBV 慢性感染或 HBV 慢性感染引起的疾病的二氢嘧啶衍生物，以及其在制药或医疗方面的应用。